Filtrer efter Last updated date SelectEfterFørFrom - To Dato Slutdato Denne uge Denne måned Seneste uge Seneste måned Category HumanCorporateVeterinaryHerbal Topic MedicinesCOVID-19PharmacovigilanceVaccinesReferralsPaediatricsRare diseasesRegulatory and procedural guidanceClinical trialsAdvanced therapiesData on medicinesCompliance and inspectionsInnovationResearch and developmentMedicine shortagesBiosimilarsSMEAntimicrobial resistanceGovernanceBrexitQuality of medicinesCorporateGeneric and hybrid medicinesEarly accessMedicines for use outside the EUFeesProduct informationScientific adviceMedical devicesMaximum residue limitMpoxBiologicalsScientific guidelinesVeterinary limited marketsCompassionate useCareersMedication errorParallel distributionPRIMEProcurement Diseases area Viral diseasesCancerImmune-system diseasesDiabetesNeurodegenerative diseasesCardiovascular diseasesHIV and AIDS Responsible body CHMP CVMP PRAC Management Board COMP PDCO CMDh HMPC CAT Patient safety Yes Efterlad dette felt tomt Filter Resultater (3800) Sort by Last update date (new to old)Last update date (old to new)A-ZZ-A Efterlad dette felt tomt EMEA public statement on Refacto (moroctocog alfa): Introduction of a change to Refacto drug product specific activity specification increase of 20% in the amount of Refacto protein in each vial 27 maj 2003News European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products, meeting of 20 to 22 May 2003 22 maj 2003Press release EMEA public statement on Replaglinide (NovoNorm/Prandin) contraindication of concomitant use of Replaglinide and Gemfibrozil 21 maj 2003News Committee for veterinary medicinal products: Meeting of 13 to 14 May 2003 15 maj 2003Press releaseVeterinary 35th meeting of the Committee for Orphan Medicinal Products 12 maj 2003Press releaseHumanRare diseases European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products, meeting of 23 to 25 April 2003 28 april 2003Press release Metabolic and cardiovascular complications of antiretroviral combination therapy in HIV-infected patients 25 april 2003News 34th meeting of the Committee for Orphan Medicinal Products 16 april 2003Press releaseHumanRare diseases Committee for veterinary medicinal products: Meeting of 8 to 9 April 2003 11 april 2003Press releaseVeterinary EU enlargement countries to join EMEA as observers from 1 April 2003 31 marts 2003Press release 1 … 346 347 348 349 350 Page 350 of 380 351 352 353 354 … 380
EMEA public statement on Refacto (moroctocog alfa): Introduction of a change to Refacto drug product specific activity specification increase of 20% in the amount of Refacto protein in each vial 27 maj 2003News
European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products, meeting of 20 to 22 May 2003 22 maj 2003Press release
EMEA public statement on Replaglinide (NovoNorm/Prandin) contraindication of concomitant use of Replaglinide and Gemfibrozil 21 maj 2003News
Committee for veterinary medicinal products: Meeting of 13 to 14 May 2003 15 maj 2003Press releaseVeterinary
35th meeting of the Committee for Orphan Medicinal Products 12 maj 2003Press releaseHumanRare diseases
European Agency for the evaluation of medicinal products: Committee for Proprietary Medicinal Products, meeting of 23 to 25 April 2003 28 april 2003Press release
Metabolic and cardiovascular complications of antiretroviral combination therapy in HIV-infected patients 25 april 2003News
34th meeting of the Committee for Orphan Medicinal Products 16 april 2003Press releaseHumanRare diseases
Committee for veterinary medicinal products: Meeting of 8 to 9 April 2003 11 april 2003Press releaseVeterinary
